Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy

Prema P. Peethambaram(Mayo Clinic), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Stephen J. Iturria(Mayo Clinic in Arizona), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ingegerd Hellström(Pacific Northwest Diabetes Research Institute), William A. Cliby(Mayo Clinic in Arizona), Patrick C. Roche(Mayo Clinic), Amy C. Clayton(WinnMed), Lynn C. Hartmann(Mayo Clinic)
Gynecologic Oncology
April 1, 2003
10.1016/s0090-8258(03)00065-9
Cited by 17

Related Papers

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|548